1. Balint E, Bates S, Vousden KH (1999) Mdm2 binds p73 alpha without targeting degradation. Oncogene 18:3923–3929
2. Calzaferri G, Forss L, Kamber I (1989) Molecular geometries by the extended huckel molecular orbital method. J Phys Chem 93:5366–5371
3. Case DA, Darden TA, Cheatham TEI, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Pearlman DA, Crowley M, Walker RC, Zhang W, Wang B, Hayik S, Roitberg A, Seabra G, Wong FK, Paesani F, Wu X, Brozell S, Tsui V, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Beroza P, Mathews DH, Schafmeister C, Ross WS, Kollmana PA (2006) AMBER 9. University of California, San Francisco
4. Chene P (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Rev Cancer 3:102–109
5. Coll Mulet L, Iglesias Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E (2006) MDM2 antagonists activate p53 and synergies with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107:4109–4114